Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia

Journal of Laboratory and Clinical Medicine

Volumn 145, Issue 6, 2005, Pages 295-304

  Scholl, Sebastian ^a,b   Krause, Claudia ^a   Loncarevic, Ivan F ^a   Müller, Rouven ^a   Kunert, Christa ^a   Wedding, Ulrich ^a   Sayer, Herbert G ^a   Clement, Joachim H ^a   Höffken, Klaus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Department of Internal Medicine II ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL LINE; CLINICAL PROTOCOL; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHODOLOGY; MINIMAL RESIDUAL DISEASE; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

ACUTE DISEASE; BASE SEQUENCE; DNA PRIMERS; FMS-LIKE TYROSINE KINASE 3; GENETIC SCREENING; HUMANS; LEUKEMIA, MYELOID; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 20644469685     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2005.03.005     Document Type: Article

References (37)

1. O. Rosnet, S. Marchetto, O. de Lapeyriere, D. Birnbaum Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family Oncogene 6 1991 1641 1650
2. S.D. Lyman, L. James, T. Vanden Bos, P. de Vries, K. Brasel, B. Gliniak Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor a proliferative factor for primitive hematopoietic cells Cell 75 1993 1157 1167
3. L.S. Rusten, S.D. Lyman, O.P. Veiby, S.E. Jacobsen The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro Blood 87 1996 1317 1325
4. H.J. McKenna, P. de Vries, K. Brasel, S.D. Lyman, D.E. Williams Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells Blood 86 1995 3413 3420
5. N. Maroc, R. Rottapel, O. Rosnet, S. Marchetto, C. Lavezzi, P. Mannoni Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase Oncogene 8 1993 909 918
6. F. Birg, M. Courcoul, O. Rosnet, F. Bardin, M.J. Pebusque, S. Marchetto Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages Blood 80 1992 2584 2593
7. D.G. Gilliland, J.D. Griffin The roles of Flt3 in hematopoieses and leukemia Blood 100 2002 1532 1542
8. M. Levis, D. Small Flt3 ITDoes matter in leukemia Leukemia 17 2003 1738 1752
9. M. Nakao, S. Yokota, T. Iwai, H. Kaneko, S. Horiike, K. Kashima Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 10 1996 1911 1918
10. P.D. Kottaridis, R.E. Gale, M.E. Frew, G. Harrison, S.E. Langabeer, A.A. Belton The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
11. C. Thiede, C. Steudel, B. Mohr, M. Schaich, U. Schakel, U. Platzbecker Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
12. Y. Yamamoto, H. Kiyoi, Y. Nakano, R. Suzuki, Y. Kodera, S. Miyawaki Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 97 2001 2434 2439
13. F.M. Abu-Duhier, A.C. Goodeve, G.A. Wilson, R.S. Care, I.R. Peake, J.T. Reilly Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia Br J Haematol 113 2001 983 988
14. H. Kiyoi, R. Ohno, R. Ueda, H. Saito, T. Naoe Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain Oncogene 21 2002 2555 2563
15. F. Hayakawa, M. Towatari, H. Kiyoi, M. Tanimoto, T. Kitamura, H. Saito Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines Oncogene 19 2000 624 631
16. M. Mizuki, R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, C. Muller Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways Blood 96 2000 3907 3914
17. K.F. Tse, G. Mukherjee, D. Small Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation Leukemia 14 2000 1766 1776
18. R. Fenski, K. Flesch, S. Serve, M. Mizuki, E. Oelmann, K. Kratz-Albers Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells Br J Haematol 108 2000 322 330
19. Y. Minami, K. Yamamoto, H. Kiyoi, R. Ueda, H. Saito, T. Naoe Different anti-apoptotic pathways between wild-type and mutated FLT3 insights into therapeutic targets in leukemia Blood 102 2003 2969 2975
20. H. Kiyoi, T. Naoe, Y. Nakano, S. Yokota, S. Minami, S. Miyawaki Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 93 1999 3074 3080
21. F.M. Abu-Duhier, A.C. Goodeve, G.A. Wilson, M.A. Gari, I.R. Peake, D.C. Rees FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group Br J Haematol 111 2000 190 195
22. W.J. Rombouts, I. Blokland, B. Lowenberg, R.E. Ploemacher Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene Leukemia 14 2000 675 683
23. S. Schnittger, C. Schoch, M. Dugas, W. Kern, P. Staib, C. Wuchter Analysis of Flt3 length mutations in 1003 patients with acute myeloid leukemia correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59 66
24. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Acute myeloid leukemia.
25. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating Flt3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the German AML Study Group, Ulm. Blood 2002;100:4372-80.
26. K.M. Murphy, M. Levis, M.J. Hafez, T. Geiger, L.C. Cooper, B.D. Smith Detection of Flt3 internal tandem mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay J Mol Diagn 5 2003 96 102
27. M. Bianchini, E. Ottaviani, T. Grafone, B. Giannini, S. Soverini, C. Terragna Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC Clin Chem 49 2003 1642 1650
28. K. Spiekermann, K. Bagrintseva, C. Schoch, T. Haferlach, W. Hiddemann, S. Schnittger A new and recurrent activating length mutation in exon 20 of the Flt3 gene in acute myeloid leukemia Blood 100 2002 3423 3425
29. K. Spiekermann, R.J. Dirschinger, R. Schwab, K. Bagrintseva, F. Faber, C. Buske The protein tyrosine kinase inhibitor SU5614 inhibits Flt3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated Flt3 Blood 101 2003 1494 1504
30. D.L. Stirewalt, S. Meshinchi, S.J. Kussick, K.M. Sheets, E. Pogosova-Agadjanyan, C.L. Willman Novel Flt3 point mutations within exon 14 found in patients with acute myeloid leukaemia Br J Haematol 124 2004 481 484
31. D. Campana Determination of minimal residual disease in leukaemia patients Br J Haematol 121 2003 823 838
32. U. Jaeger, B. Kainz Monitoring of minimal residual disease in AML the right time for real time Ann Hematol 82 2003 139 147
33. D.L. Stirewalt, C.L. Willman, J.P. Radich Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific Leuk Res 25 2001 1085 1088
34. W. Bi, J. Stambrook Detection of known mutation by proof-reading PCR Nucl Acids Res 26 1998 3073 3075
35. P. Song, S. Li, B. Meibohm, A.O. Gaber, M.R. Honaker, M. Kotb Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using RealTime polymerase chain reaction MDR1 single nucleotide polymorphism genotyping assay AAPS PharmSci 4 4 2002 E29
36. K. Bagrintseva, R. Schwab, T.M. Kohl, S. Schnittger, S. Eichenlaub, J.W. Ellwart Mutations in the tyrosine kinase domain of Flt3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in Flt3-ITD-transformed hematopoietic cells Blood 103 2004 2266 2275
37. L.Y. Shih, C.F. Huang, J.H. Wu, P.N. Wang, T.L. Lin, P. Dunn Heterogeneous patterns of Flt3 Asp835 mutations in relapsed de novo acute myeloid leukemia a comparative analysis of 120 paired diagnostic and relapsed bone marrow samples Clin Cancer Res 10 2004 1326 1332